Vessel dilator and C-type natriuretic peptide enhance the proliferation of human osteoblasts

Pediatric Research

Volumn 68, Issue 5, 2010, Pages 405-408

  Lenz, Anne ^a   Bennett, Meghan ^a   Skelton, William P ^a   Vesely, David L ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; MITOGEN ACTIVATED PROTEIN KINASE; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE C; UNCLASSIFIED DRUG; VESSEL DILATOR;

ACHONDROPLASIA; ARTICLE; CELL PROLIFERATION; CELL STIMULATION; CONCENTRATION (PARAMETERS); DOSE RESPONSE; ENZYME SYNTHESIS; HALF LIFE TIME; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; OSTEOBLAST; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT STATURE; VASODILATATION;

ADOLESCENT; ANIMALS; ATRIAL NATRIURETIC FACTOR; CELL LINE; CELL PROLIFERATION; CYCLIC GMP; FEMALE; HUMANS; MICE; NATRIURETIC PEPTIDE, C-TYPE; OSTEOBLASTS; PEPTIDE FRAGMENTS; RATS;

EID: 77958484651     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1203/PDR.0b013e3181ef7636     Document Type: Article

References (33)

1. Karsenty G, Wagner EF 2002 Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2:389-406
2. Olsen BR, Regiano AM, Wang W 2000 Bone development. Annu Rev Cell Dev Biol 16:191-220
3. Hagiwara H, Sakaguchi H, Itakura M, Yoshimoto T, Furuya M, Tanaka S, Hinose S 1994 Autocrine regulation of rat chondrocyte proliferation by natriuretic peptide C and its receptor, natriuretic peptide receptor-B. J Biol Chem 269:10729-10733
4. Hagiwara H, Inoue A, Yamaguchi A, Yokose S, Furuya M, Tanaka S, Hirose S 1996 cGMP produced in response to ANP and CNP regulates proliferation and differentiation of osteoblastic cells. Am J Physiol 270:C1311-C1318
5. Suda M, Tanaka K, Fukushima M, Natsui K, Yasoda A, Komatsu Y, Ogawa Y, Itoh H, Nakao K 1996 C-type natriuretic peptide as an autocrine/paracrine regulator of osteoblasts. Biochem Biophys Res Commun 223:1-6
6. Yasoda A, Ogawa Y, Suda M, Tamura N, Mori K, Sakuma Y, Chusho H, Shiota K, Tanaka K, Nakao K 1998 Natriuretic peptide regulation of endochondral ossification. Evidence for possible roles of the C-type natriuretic peptide/guanylyl cyclase-B pathway. J Biol Chem 273:11695-11700
7. Mericq V, Uyeda JA, Barnes KM, De Luca F, Baron J 2000 Regulation of fetal rat bone growth by C-type natriuretic peptide and cGMP. Pediatr Res 47:189-193
8. Kalra PR, Anker SD, Struthers AD, Coats AJ 2001 The role of C-natriuretic peptide in cardiovascular medicine. Eur Heart J 22:997-1007
9. Daggubati S, Parks JR, Overton RM, Cintron G, Schocken DD, Vesely DL 1997 Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohor-mone peptides compared as early heart failure indicators. Cardiovasc Res 36:246-255
10. Pfeifer A, Aszodi A, Seidler O, Ruth P, Hofmann F, Fassler R 1996 Intestinal secretory defects and dwarfism in mice lacking cGMP-dependent protein kinase II. Science 274:2082-2086
11. Yasoda A, Komatsu Y, Chusho H, Miyazawa T, Ozasa A, Miura M, Kurihara T, Rogi T, Tanaka S, Suda M, Tamura N, Ogawa Y, Nakao K 2004 Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway. Nat Med 10:80-86
12. Chusho H, Tamura N, Ogawa Y, Yasoda A, Suda M, Miyazawa T, Nakamura K, Nakao K, Kurihara T, Komatsu Y, Itoh H, Takana K, Saito Y, Katsuki M, Nakao K 2001 Dwarfism and early death in mice lacking C-type natriuretic peptide. Proc Natl Acad Sci \USA 98:4016-4021
13. Yoder AR, Kruse AC, Earhart CA, Ohlendorf DH, Potter LR 2008 Reduced ability to C-type natriuretic peptide (CNP) to activate natriuretic peptide receptor B (NPR-B) causes dwarfism in 1bab-/-mice. Peptides 29:1575-1581
14. Bocciardi R, Giorda R, Buttgereit J, Gimelli S, Divizia MT, Beri S, Garofalo S, Tavella S, Lerone M, Zuffardi O, Bader M, Ravazzolo R, Gimelli G 2007 Overex-pression of the C-type natriuretic peptide (CNP) is associated with overgrowth and bone anomalies in an individual with balanced t(2;7) translocation. Hum Mutat 28:724-731
15. Tamura N, Doolittle LK, Hammer RE, Shelton JM, Richardson JA, Garbers DL 2004 Critical roles of the guanylyl cyclase B receptor in endochondral ossification and development of female reproductive organs. Proc Natl Acad Sci \USA 101:17300-17305
16. Tsuji T, Kunieda T 2005 A loss-of-function mutation in natriuretic peptide receptor 2 (Npr2) gene is responsible for disproportionate dwarfism in cn/cn mouse. J Biol Chem 280:14288-14292
17. Miyazawa T, Ogawa Y, Chusho H, Yasoda A, Tamura N, Komatsu Y, Pfeifer A, Hofmann F, Nakao K 2002 Cyclic GMP-dependent protein kinase II plays a critical role in C-type natriuretic peptide-mediated endochondral ossification. Endocrinology 143:3604-3610
18. Teixeira CC, Agoston H, Beier F 2008 Nitric oxide, C-type natriuretic peptide and cGMP as regulators of endochondral ossification. Dev Biol 319:171-178
19. Nakao K, Sugawara A, Morii N, Sakamoto M, Yamada T 1986 The pharmacokinetics of a-human natriuretic polypeptide in healthy subjects. Eur J Clin Pharmacol 31:101-103
20. Yandle TG, Richards AM, Nicholls MG, Cuneo R, Espiner EA, Livesey JH 1986 Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man. Life Sci 38:1827-1833
21. Brenner BM, Ballerman BM, Gunning ME, Zeidel ML 1990 Diverse biological action of atrial natriuretic peptide. Physiol Rev 70:665-699
22. Vesely DL 2003 Natriuretic peptides and acute renal failure. Am J Physiol Renal Physiol 285:F167-F177
23. Vesely DL 2007 Natruiretic hormones. In: Alpern RJ, Herbert SC (eds) Seldin and Giebisch's The Kidney: Physiology and Pathophysiology. 4th ed. Elsevier, Inc., Amsterdam, The Netherlands, pp 947-977
24. Ackerman BH, Overton RM, McCormick MT, Schocken DD, Vesely DL 1997 Disposition of vessel dilator and long-acting natriuretic peptide in healthy humans after a one-hour infusion. J Pharmacol Exp Ther 282:603-608
25. Vesely DL, Douglass MA, Dietz JR, Gower WR Jr, McCormick MT, Rodriguez-Paz G, Schocken DD 1994 Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans. Circulation 90:1129-1140
26. Harris SA, Enger RJ, Riggs BL, Spelsberg TC 1995 Developmental and characterization of a conditionally immortalized human fetal osteoblastic cell line. J Bone Miner Res 10:178-186
27. Cory AH, Owen TC, Barltop HA, Cory JG 1991 Useof aqueous soluble tetrazolium/ formazan assay for growth assays in culture. Cancer Commun 3:207-212
28. Sun Y, Eichelbaum EJ, Wang H, Vesely DL 2007 Vessel dilator and kaliuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells. Anticancer Res 27:1387-1392
29. Murakami S, Balmes G, McKinney S, Zhang Z, Givol D, de Crombrugghe B 2004 Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype. Genes Dev 18:290-305
30. Ozasa A, Komatsu Y, Yasoda A, Muira M, Sakuma Y, Nakatsuru Y, Arai H, Itoh N, Nakao K 2005 Complementary antagonistic actions between C-type natriuretic peptide and the MAPK pathway through FGFR-3 in ATDC5 cells. Bone 36:1056-1064
31. Sun Y, Eichelbaum EJ, Wang H, Vesely DL 2006 Vessel dilator and kaliuretic peptide inhibit activation of ERK 1/2 in human prostate cancer cells. Anticancer Res 26:3217-3222 (Pubitemid 44701488)
32. Sun Y, Eichelbaum EJ, Wang H, Vesely DL 2007 Insulin and epidermal growth factor activation of ERK 1/2 and DNA synthesis is inhibited by four cardiac hormones. J. Cancer Mol 3:113-120
33. Rubin JE, Rubin CT 2009 Biology, physiology, and morphology of bone. In: Firestein GS, Budd RC, Harris ED Jr, McInnes IB, Ruddy S, Sergent SS (eds) Kelly's Textbook of Rheumatology. 8th ed. Elsevier, Philadelphia, PA, pp 71-91